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Role of Phospholipase Cβ3
C 3 Phosphorylation in the Desensitization of Cellular
Responses to Platelet-Activating Factor
Abstract
Platelet-activating factor (PAF) stimulates a diverse array of cellular responses through receptors coupled
to G proteins that activate phospholipase C (PLC). Truncation of the cytoplasmic tail of the receptor to
remove phosphorylation sites (mutant PAF receptor, mPAFR) results in enhancement of PAF-stimulated
responses. Here we demonstrate that PAF or phorbol 12- myristate 13-acetate (PMA) pretreatment
inhibited wild type PAFR-induced PLC- mediated responses by ~90%, whereas these responses to the
phosphorylation- deficient mPAFR were inhibited by ~50%, despite normal G protein coupling, suggesting
a distal inhibitory locus. PAF and PMA, as well as a membrane permeable cyclic AMP analog, stimulated
phosphorylation of PLCβ3. A protein kinase C (PKC) inhibitor blocked phosphorylation of PLCβ3
stimulated by PAF and PMA but not by cAMP. Activation of protein kinase A (PKA) by cAMP did not result
in inhibition of Ca2+ mobilization stimulated by PAF. In contrast, cAMP did inhibit the response to
formylpeptide chemoattractant receptor. These data suggest that homologous desensitization of PAFmediated responses is regulated via phosphorylation at two levels in the signaling pathway, one at the
receptor and the other at PLCβ3 mediated by PKC but not by PKA. Phosphorylation of PLCβ3 by PKA
could explain the inhibition of formylpeptide chemoattractant receptor signaling by cAMP. As PAF and
formylpeptide chemoattractant receptors activate PLC via different G proteins, phosphorylation of PLCβ3
by PKC and PKA could provide distinct regulatory control for classes of G protein-coupled receptors.
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Desensitization of Cellular
Responses to Platelet-activating
Factor*
(Received for publication, December 20, 1996, and in revised
form, February 13, 1997)
Hydar Ali‡§, Ian Fisher‡, Bodduluri Haribabu‡,
Ricardo M. Richardson‡,
and Ralph Snyderman‡¶
From the Departments of ‡Medicine and ¶Immunology,
Duke University Medical Center,
Durham, North Carolina 27710

Platelet-activating factor (PAF) stimulates a diverse
array of cellular responses through receptors coupled to
G proteins that activate phospholipase C (PLC). Truncation of the cytoplasmic tail of the receptor to remove
phosphorylation sites (mutant PAF receptor, mPAFR)
results in enhancement of PAF-stimulated responses.
Here we demonstrate that PAF or phorbol 12-myristate
13-acetate (PMA) pretreatment inhibited wild type
PAFR-induced PLC-mediated responses by ;90%,
whereas these responses to the phosphorylation-deficient mPAFR were inhibited by ;50%, despite normal G
protein coupling, suggesting a distal inhibitory locus.
PAF and PMA, as well as a membrane permeable cyclic
AMP analog, stimulated phosphorylation of PLCb3. A
protein kinase C (PKC) inhibitor blocked phosphorylation of PLCb3 stimulated by PAF and PMA but not by
cAMP. Activation of protein kinase A (PKA) by cAMP did
not result in inhibition of Ca21 mobilization stimulated
by PAF. In contrast, cAMP did inhibit the response to
formylpeptide chemoattractant receptor. These data
suggest that homologous desensitization of PAF-mediated responses is regulated via phosphorylation at two
levels in the signaling pathway, one at the receptor and
the other at PLCb3 mediated by PKC but not by PKA.
Phosphorylation of PLCb3 by PKA could explain the
inhibition of formylpeptide chemoattractant receptor
signaling by cAMP. As PAF and formylpeptide chemoattractant receptors activate PLC via different G proteins,
phosphorylation of PLCb3 by PKC and PKA could provide distinct regulatory control for classes of G proteincoupled receptors.

Platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3phosphocholine, PAF)1 plays important roles in inflammation
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and has physiological effects on cardiovascular, reproductive,
and central nervous systems (1). PAF mediates its effects via
the activation of a seven transmembrane domain G proteincoupled receptor (2, 3). One of the consequences of PAF receptor activation is the phospholipase C (PLC)-mediated hydrolysis of phosphatidylinositol 4,5-bisphosphate leading to the
activation of protein kinase C (PKC) and mobilization of intracellular Ca21 (4). Molecular cloning has revealed three classes
of PLC: PLCb, PLCg, and PLCd, and each of these occur in
several isoforms (5, 6). All four PLC b isoforms are activated to
varying extent by a subunit of a class of G proteins known as Gq
(7–10). PLCb2 and PLCb3 are also activated by the bg subunit
of the Gi family of G proteins (11–13). Tyrosine phosphorylation
of PLCg is required for its activation, but the mechanism by
which PLCd is activated is unknown (5). PAFR couples to both
pertussis toxin (Ptx)-sensitive and Ptx-insensitive G proteins
in a variety of cells (4, 14, 15). In B cells and platelets, PAF
activates PLCg (16, 17), but the identity of PLCs activated by
PAF in phagocytic leukocytes is unknown.
In phagocytes, PAF-stimulated G protein activation and
Ca21 mobilization are desensitized by prior treatment of cells
with PAF and other chemoattractants such as the formylated
peptides, C5a and interleukin-8 (18). This laboratory has developed stably transfected RBL-2H3 cells to study molecular
mechanisms of leukocyte chemoattractant receptor regulation
(15, 19 –21). Using wild type and phosphorylation-deficient
PAFR expressed in this cell line, we now describe the novel
finding that homologous desensitization of PAF-mediated
phosphoinositide hydrolysis and Ca21 mobilization is mediated
via two processes; one at the level of receptor phosphorylation
and the other at the level of PLC activation apparently by
PKC-dependent phosphorylation of PLCb3.
EXPERIMENTAL PROCEDURES

Materials—Bisindolylmaleimide or GF 109203X (BIM), 8-(4-chlorophenylthio)-adenosine 39-cyclic monophosphate (Cpt-cAMP) and the tyrosine kinase inhibitor PP1 were purchased from Calbiochem. Affinity
purified polyclonal antibodies against PLCb1, PLCb2, and PLCb3 were
obtained from Santa Cruz Biotechnology. ECL Western blot analysis kit
was purchased from Amersham Corp. Mouse monoclonal IgE and antigen (dinitrophenylated BSA) were generously provided by Drs. Juan
Rivera and Henry Metzger (National Institutes of Health). All other
materials were obtained from sources previously described (15).
Cell Culture, Phosphoinositide Hydrolysis, and Ca21 Mobilization—
RBL-2H3 cells stably expressing ;3 3 104 receptors for PAFR and
mPAFR were used (21). The cells were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 15% fetal bovine serum, glutamine (2
mM), penicillin (100 units/ml), and streptomycin (100 mg/ml) (19). For
phosphoinositide hydrolysis, cells (5 3 104 cells/well) were subcultured
overnight in 96-well tissue culture plate with 1 mCi/ml of [3H]inositol in an
inositol-free medium supplemented with 10% dialyzed fetal bovine serum.
Cells were washed with HEPES-buffered saline containing 10 mM LiCl
and 0.1% BSA and stimulated, and the generation of total [3H]inositol
phosphates was determined. For Ca21 mobilization, cells (3 3 106) were
loaded with 1 mM indo-1/AM in the presence of 1 mM pluoronic acid for 30
min at room temperature. Cells were washed and resuspended in 1.5 ml
HEPES-buffered saline, and intracellular Ca21 mobilization was determined as described previously (19).
PAF receptor; mPAFR, mutant PAFR; PLC, phospholipase C; PMA,
phorbol 12-myristate 13-acetate; RBL, rat basophilic leukemia; CptcAMP, 8-(4-chlorophenylthio)-adenosine 39-cyclic monophosphate;
PKA, protein kinase A, PKC; protein kinase C; BIM, bisindolylmaleimide; Ptx, pertussis toxin; BSA, bovine serum albumin; PAGE, polyacrylamide gel electrophoresis; GTPgS, guanosine 59-3-O-(thio)triphosphate.
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TABLE I
Desensitization of PAF-mediated Ca21 mobilization
RBL-2H3 cells (3 3 106) expressing mPAFR or PAFR were loaded
with indo-1 and stimulated with PAF (10 nM), and peak Ca21 mobilization was determined as described (19). For homologous desensitization, PAF-stimulated cells were washed, and 5 min later they were
restimulated with PAF (10 nM) and peak Ca21 mobilization was determined. Cells were also preincubated with PMA (100 nM), and 5 min
later they were stimulated with PAF (10 nM) and peak Ca21 mobilization was determined. The basal unstimulated intracellular Ca21 concentration was 150 6 10 and was subtracted from the values shown,
which are the means 6 S.E. of three different experiments.
Cells/treatment

mPAFR
PAF 3 PAF
PMA 3 PAF
PAFR
PAF 3 PAF
PMA 3 PAF

Ca21 mobilization

Desensitization

nM

%

517 6 15 3 240 6 19
0 6 0 3 264 6 12

53
51

617 6 40 3 48 6 4
0 6 0 3 43 6 5

92
93

Western Blotting and Immunoprecipitation of PLCb3—For Western
blotting, lysate (150 mg protein) from RBL-2H3 cells, and for comparison, lysates from bovine brain, COS cells, and HL-60 cells were resolved
on a 6% SDS-PAGE gel. The proteins were transferred to nitrocellulose
membrane, blocked with 3% milk, and incubated with 1.5 mg/ml of
different anti-PLCb antibodies. The immunoreactive proteins were
visualized using ECL Western blotting detection system. Phosphorylation of PLCb3 was performed essentially as described for the epitopetagged chemoattractant receptors (19). Briefly, RBL-2H3 cells (3 3 106)
were subcultured overnight in 60-mm tissue culture dishes. The following day, cells were washed twice with 5 ml of phosphate-free Dulbecco’s
modified Eagle’s medium and incubated in the same medium plus
[32P]orthophosphate (150 mCi/dish) for 90 min. The labeled cells were
stimulated, and PLCb3 was immunoprecipitated from cell lysate with
anti-PLCb3 antibody. The proteins were resolved on a 6% SDS-PAGE
gel and visualized by autoradiography.
RESULTS AND DISCUSSION

The mechanism of PAF receptor desensitization was studied
using the rat basophilic leukemia (RBL-2H3) cells expressing
wild type PAFR and a mPAFR in which the cytoplasmic tail was
truncated to delete potential phosphorylation sites (21). In contrast to PAFR, mPAFR was resistant to both ligand and PKCinduced receptor phosphorylation and desensitization of G protein coupling, as measured by [35S]GTPgS binding to membranes
(21, 22). However, when indo-1-loaded cells expressing mPAFR
were stimulated with PAF (10 nM), washed, and restimulated
with PAF (10 nM), the peak Ca21 response was still homologously
desensitized by ;50% (Table I). PMA also inhibited mPAFRmediated Ca21 mobilization by ;50%, suggesting a locus of inhibition distal to G protein activation. In cells expressing wild
type PAFR, both PAF and PMA inhibited PAF-induced Ca21
mobilization by .90%. PMA also caused substantial inhibition of
mPAF-induced generation of inositol phosphates and completely
blocked the response to PAF (Fig. 1). To further test the role of
PKC on PAFR desensitization, cells expressing mPAFR and
PAFR were treated with PMA (100 nM) overnight to deplete PKC
or incubated with the PKC-inhibitor bisindolylmaleimide for 10
min to block the activity of the enzyme. PAF-stimulated generation of inositol phosphates was then determined. Under both of
these conditions, PAF-induced responses were enhanced 2–3-fold
in cells expressing mPAFR (Fig. 1). Overnight PMA treatment
did not enhance the response to PAF in cells expressing PAFR,
but bisindolylmaleimide did potentiate the response to PAF. Because PMA-induced PKC depletion involves activation of the
enzyme, it was possible that the differential effect of PMA on
mPAFR and PAFR cells resulted from PKC-induced phosphorylation and down-regulation of PAFR but not mPAFR. Indeed,
treatment of cells with PMA (100 nM, overnight) resulted in
;50% decrease of the wild type PAFR expression but had no

FIG. 1. Regulation of PAF-stimulated generation of [3H]inositol phosphates by PKC. RBL-2H3 cells expressing mPAFR (A) and
PAFR (B) were cultured overnight with [3H]inositol in the absence
(control, f, ●) and the presence of PMA (100 nM, r). The next day, cells
were washed in a HEPES-buffered saline containing 10 mM LiCl, preincubated with the same buffer (f, v, r), PMA (100 nM, å), or BIM (10
mM, E) and then stimulated with different concentrations of PAF, and
the generation of total [3H]inositol phosphates were determined. Data
are the means 6 S.E. of one of three similar experiments performed in
triplicate.

effect on mPAFR as measured by the PAFR antagonist [3H]WEB
2086 binding to intact cells (data not shown). These data suggest
that homologous desensitization of PAF-mediated cellular responses is mediated by two processes. One involves receptor
phosphorylation, presumably by PKC and a G protein-coupled
receptor kinase, which uncouple the receptor from G proteins
(21). In addition, a new mechanism was identified as a consequence of PKC-induced modification of a component distal to G
protein activation but proximal to the generation of inositol
phosphates.
Although most G protein-coupled receptors activate PLCb,
angiotensin receptors in smooth muscle cells and PAF receptors in B cells and platelets cause tyrosine phosphorylation and
activation of PLCg (16, 17, 23). The molecular mechanism by
which G protein-coupled receptors activate PLCg has yet to be
determined. PMA, which causes serine phosphorylation of
PLCg (24), leads to reduction of both tyrosine phosphorylation
of PLCg and generation of inositol phosphates stimulated by
cross-linking of cell surface IgE receptors with antigen (25, 26).
This suggests that if PAF activates PLCg, a similar modification of PLCg by PKC could be involved in its homologous
desensitization. However, the tyrosine kinase inhibitor PP1
(27), which blocked antigen (IgE)-stimulated Ca21 mobilization
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TABLE II
Effects of tyrosine phosphorylation inhibition or cAMP elevation on
PAF, fMLP, and IgE-mediated Ca21 mobilization
RBL-2H3 cells coexpressing fMLP and PAF receptors (21) were incubated with IgE (0.2 mg/ml) overnight to saturate cell surface IgE receptors. The following day cells were loaded with indo-1 for 30 min in the
absence (control) and the presence of the tyrosine kinase inhibitor, PP1
(10 mM), and Ca21 mobilization in response to PAF (0.2 nM), fMLP (1.0
nM), and antigen, dinitrophenylated (DNP) BSA (1 ng/ml) was determined. Indo-1-loaded cells were also preincubated with the membrane
permeable cAMP analog, cpt-cAMP (1 mM, 5 min), and its effect on peak
Ca21 mobilization was tested. Values are the means 6 S.E. of four
experiments. The numbers in parenthesis represent the percentage of
inhibition of response as compared with control.
Stimulation

Control

PP1 (10 mM)

cpt-cAMP (1 mM)

PAF
fMLP
DNP BSA/IgE

495 6 23
249 6 3.5
376 6 22

531 6 51 (27)
250 6 3 (0)
90 6 11 (76)

548 6 25 (210)
44 6 12 (82)
103 6 3 (72)

FIG. 2. Identification of PLCb isozymes expressed in RBL-2H3
cells. Lysate (150 mg protein) from RBL-2H3 cells, bovine brain, COS,
and HL-60 cells were resolved on a 6% SDS-gel and analyzed by Western blotting using antibodies directed against PLCb1, PLCb2, and
PLCb3. This experiment was repeated three times with similar results.

by .70%, presumably by inhibiting tyrosine phosphorylation of
PLCg, had no effect on PAF-mediated responses (Table II).
Elevation of intracellular cAMP has also been shown to cause
serine phosphorylation of PLCg and inhibition of antigen-stimulated responses (24). As shown in Table II, the membrane
permeable cAMP analog 8-(4-chlorophenylthio)-adenosine 39cylic monophosphate (cpt-cAMP) substantially inhibited IgEmediated Ca21 mobilization but had no effect on the PAFmediated response. These data suggest that unlike B cells and
platelets (16, 17) PAF does not activate PLCg in RBL-2H3
cells and that PKA does not down-regulate PAF-mediated
responses.
We therefore sought to determine whether a PLCb isoform is
activated by PAF in RBL-2H3 cells. To identify the PLCb
isoforms expressed in RBL-2H3 cells, their lysates and lysates
from bovine brain, COS and HL-60 cells were separated by
SDS-PAGE, and the presence of PLCb1, PLCb2, and PLCb3
was determined by Western blotting using PLCb isoform-specific antibodies. All cells tested, including RBL-2H3 cells, expressed PLCb3 in different amounts (Fig. 2). Although PLCb1
and PLCb2 were expressed at high levels in brain and HL-60
cells, respectively, neither could be detected in RBL-2H3 cells
(Fig. 2).
Studies with purified G proteins and PLC revealed that
PLCb1 and PLCb3 are equally responsive to activation by Gaq
(28). It was therefore possible that in RBL-2H3 cells, which do
not express PLCb1, PAF activates PLCb3 and that PKC-induced modification of this enzyme accounts for the distal component of PAFR homologous desensitization. To test this hypothesis, cells were labeled with [32P]orthophosphate and
stimulated with PAF, and cell lysate was immunoprecipitated
with PLCb3-specific antibody. As shown in Fig. 3 (A and B),
PAF caused phosphorylation of PLCb3 in a dose- and time-dependent manner. PLCb3 phosphorylation was detectable at

FIG. 3. Phosphorylation of PLCb3. 32P-labeled RBL-2H3 cells expressing PAFR were stimulated with different concentrations of PAF
for 5 min (A) or with a fixed concentration of PAF (10 nM) for different
times (B). C, effects of bisindolylmaleimide on PLCb3 phosphorylation.
32
P-Labeled cells expressing PAFR were preincubated with BIM (10 mM;
10 min) and stimulated with PAF (10 nM), PMA (100 nM), or cpt-cAMP
(1 mM) for 5 min. D, U937 cells and J774.1 cells were labeled with 32P
as described for RBL-2H3 cells, stimulated with PAF (10 nM), PMA (100
nM), and cpt-cAMP (1 mM) for 5 min. Cells were lysed, immunoprecipitated with anti-PLCb3 antibody, and analyzed by SDS-PAGE and autoradiography. Results shown are from one of four similar experiments.

physiologic PAF concentration of 0.3 nM and was maximum by
10 nM. PAF-induced PLCb3 phosphorylation was rapid,
reached a maximum by 15 s, and remained elevated for 10 min.
To determine whether there was a correlation between PKCmediated PLCb3 phosphorylation and inhibition of PAF-stimulated responses, cells were treated with or without the PKC
inhibitor bisindolylmaleimide, stimulated with PAF (10 nM)
and PMA (100 nM), and PLCb3 phosphorylation was determined. As shown in Fig. 3C, PAF- and PMA-induced PLCb3
phosphorylation was almost completely inhibited by bisindolylmaleimide. Cpt-cAMP also phosphorylated PLCb3 presumably
through activation of PKA, and this phosphorylation was not
inhibited by bisindolylmaleimide. PLCb3 phosphorylation was
also tested in two other cell lines that endogenously express
PAF receptors. These were the human monocyte-like U937
cells and the murine macrophage-like J774.1 cells. In both
cases, PAF, PMA, and cpt-cAMP stimulated phosphorylation of
PLCb3 (Fig. 3D).
The effect of cAMP elevation on PLC activation was determined using the RBL-2H3 cells coexpressing PAF and
formylpeptide receptors. In such cells, cpt-cAMP did not inhibit
Ca21 mobilization to PAF, although it did inhibit the response
of the formylpeptide receptor (Table II). Furthermore, in cells
expressing mPAFR, cpt-cAMP (1 mM, 5 min) had no effect
on PAF-stimulated generation of [3H]inositol phosphates,
whereas PMA (100 nM, 5 min) blocked this response by ;50%.

Phosphorylation of PLCb3
Preincubation of cells with cpt-cAMP had no effect on PMAmediated inhibition of PAF-stimulated response (data not
shown). These data support the hypothesis that PLCb3 is likely
activated by PAFR and that PLCb3 phosphorylation by PKC,
but not by PKA, is responsible for one component of PAFR
homologous desensitization.
PLCb1 is phosphorylated by PKC (29), and PLCb2 is phosphorylated by PKA (30). The present study revealed that both
PKC and PKA phosphorylate of PLCb3 in vivo (Fig. 3C). More
importantly, phosphorylation of PLCb3 by the different protein
kinases appears to be associated with distinct functional consequences. Although phosphorylation of PLCb3 by PKC resulted in the inhibition of responses stimulated by PAF, its
phosphorylation by PKA was not associated with such inhibition. On the other hand, PKA activation by cpt-cAMP inhibited
formylpeptide receptor-mediated responses. In RBL-2H3 cells
PAF receptors activate PLC predominantly via a Ptx-insensitive G protein, whereas formylpeptide-mediated response is
completely blocked by Ptx (15, 19). Therefore, differential inhibition of responses to PAF and formylpeptide by PKC and PKA
is likely due to the different G protein subunits these receptors
utilize to activate PLC. It was demonstrated in vitro that Gaq
and Gbg released from Ptx-sensitive G protein interact with
distinct regions of PLCb3 to activate the enzyme (28). This led
Smrcka and Sternweis to propose that different receptors that
utilize Gq or Gi could activate PLCb3 by producing Gaq or Gbg
(28). The data presented herein support this hypothesis and
provide a molecular basis for the differential regulation of
Gaq- and Gbg-mediated activation of PLCb3. It is likely that
PKC and PKA phosphorylate PLCb3 on distinct sites that block
its activation by Gaq and Gbg, respectively.
Similar to RBL-2H3 cells, many human cell lines and tissues
express PLCb3 but not PLCb1 or PLCb2 (9, 11, 28, 31). Given
the duality of PLCb3 activation by both Gaq and Gbg and its
ubiquitous tissue distribution, phosphorylation of PLCb3 by
PKC and PKA may be general mechanisms by which functions
of different G protein/PLC-coupled receptors are regulated.
Acknowledgments—We thank Drs. Juan Rivera and Henry Metzger
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